Trial Profile
A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (HLX10) in Combination With Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection (HLX04) in Patients With Advanced Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 21 Apr 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Serplulimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Shanghai Henlius Biotech
- 18 Mar 2022 Interim results (n=26) presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 22 May 2019 Planned number of patients changed from 24 to 30.
- 30 Apr 2019 Status changed from not yet recruiting to recruiting.